Welcome to our dedicated page for QHSLab SEC filings (Ticker: USAQ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The QHSLab, Inc. (OTCQB: USAQ) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including Form 10-K annual reports, Form 10-Q quarterly reports, and Form 8-K current reports. QHSLab is a Nevada corporation with common stock registered under Section 12(g) of the Securities Exchange Act of 1934, and it uses these filings to report on its digital health and medical device business focused on primary care screening, assessments, and point-of-care diagnostics.
For investors analyzing USAQ, the company’s periodic reports detail revenue contributions from Integrated Service Program services, allergy diagnostic kits, immunotherapy, clinical study revenue, subscriptions, and related categories. These filings also discuss gross margin trends, operating performance, and risk factors relevant to a healthcare technology and medical devices issuer. Annual Form 10-K and quarterly Form 10-Q documents are key sources for understanding QHSLab’s business model, segment mix, and cash flow profile.
QHSLab’s Form 8-K current reports provide additional insight into material events. Recent 8-Ks describe a note repurchase agreement that extinguished defaulted convertible promissory notes, a promissory note modification and partial conversion, and a private placement of common stock and warrants to accredited investors. Other 8-Ks furnish press releases about product launches such as the Q-Cog™ cognitive assessment, corporate presentations, shareholder letters, and financial and operational updates.
On Stock Titan, these SEC filings are updated in near real time from EDGAR and are accompanied by AI-powered summaries that highlight the most important points in each document. Users can quickly see what changed in a new 10-Q, how a financing or debt restructuring described in an 8-K affects capital structure, and where to find details on revenue composition, digital health initiatives, and risk disclosures. Form 4 insider transaction reports, when filed, can also be reviewed to track equity activity by QHSLab officers, directors, or significant shareholders.
QHSLab, Inc. reported a strong turnaround for fiscal 2025, with revenue rising to $2,691,741, about 26% higher than 2024. Growth was driven largely by its Integrated Service Program for primary care practices.
Gross profit increased to $1,810,849 and gross margin improved to 67.3%, showing a shift toward higher-margin digital health services. The company moved to net income of $457,417 from a prior-year net loss, helped by lower interest expense and a gain of about $1.15 million from extinguishing convertible debt.
QHSLab strengthened its balance sheet as cash rose to $636,157 and current liabilities fell from roughly $2.4 million to about $450,000 at year-end 2025. Integrated Service Program revenue grew 74% year-over-year to $1,121,134, while immunotherapy sales also increased, supporting a more diversified and scalable business model.
QHSLab, Inc. (USAQ) reports a small 2025 profit while warning that its ability to continue as a going concern is uncertain. The digital health and allergy-diagnostics company earned net income of $457,417 in 2025, helped by a one-time $666,000 gain from extinguishing debt, after a $259,239 loss in 2024.
Revenue rose to $2,691,741 in 2025 from $2,131,926 in 2024, driven by its QHSLab SaaS platform and AllergiEnd allergy products sold to independent primary care practices. The business still relies on external funding, taking $362,168 of loans and raising $499,998 of equity in 2025, and had $201,788 of notes and loans outstanding at year-end.
The company flags material weaknesses in internal controls due to limited staff and discloses significant regulatory, data-privacy and reimbursement risks tied to operating in heavily regulated healthcare and handling protected health information. As of March 30, 2026, QHSLab had 12 employees and 15,032,788 common shares outstanding; non‑affiliate holders owned 7,438,363 shares valued at $1,562,056 as of June 30, 2025.
QHSLab, Inc. Schedule 13G/A: Nicholas Peters reported beneficial ownership of 1,161,049 shares of common stock, representing 8.65% of the class. The filing states he holds both sole and shared voting power and dispositive power over 1,161,049 shares. The form is signed 02/25/2026.
QHSLab, Inc. reports a Schedule 13G showing beneficial ownership of 8.65% represented by 1,161,049 shares of Common Stock. The filing lists Nicholas Peters as the beneficial owner with sole and shared voting and dispositive power over 1,161,049 shares.
The filing is signed by Nicholas Peters and dated 02/09/2026.
QHSLab, Inc. filed a current report describing that, on January 26, 2026, it issued a press release with preliminary unaudited 2025 financial results. The release, furnished as Exhibit 99.1, highlights strong revenue growth, expanding margins, and significant debt reduction, indicating improved sales performance, profitability, and balance sheet strength for 2025.
The company states that this information is provided under Regulation FD and is furnished rather than filed, so it is not automatically subject to certain Exchange Act liabilities or incorporated into other SEC reports unless specifically referenced. QHSLab also notes that it uses its website and social media channels, along with press releases, to share business and financial information that may be considered material for investors.
QHSLab, Inc. entered into a Note Repurchase Agreement with MedScience Research Group, Inc. Under this deal, QHSLab repurchased, cancelled, and extinguished a promissory note originally issued on June 23, 2021 in the principal amount of $750,000. As of December 31, 2025, the outstanding principal and accrued interest on the note totaled $470,529.
In exchange for eliminating this debt, QHSLab issued 1,568,432 shares of its common stock, as directed by MedScience. The company states that its Chief Executive Officer, who is a minority shareholder and service provider to MedScience, did not receive any personal distribution or other consideration from the transaction. The note is now fully satisfied and of no further force or effect.
The company characterizes this transaction as simplifying its capital structure, removing a related-party debt obligation, and improving the clarity of its balance sheet and financial reporting. The shares were issued in a private, unregistered offering under Section 4(a)(2) and/or Regulation D of the Securities Act as non-cash consideration for cancellation of indebtedness.
QHSLab, Inc. reported that it issued a press release on January 16, 2026 announcing that it has initiated a board expansion process intended to strengthen corporate governance and support its next phase of growth. The press release is furnished as Exhibit 99.1 under a Regulation FD disclosure item and is not deemed filed for liability purposes or automatically incorporated into other SEC documents.
The company also reminds investors that it uses its website and social media accounts on Twitter, LinkedIn, Facebook, and Instagram, along with press releases, to share public information that could be considered material. The filing’s exhibit index lists the board expansion press release and the cover page interactive data file.
QHSLab, Inc. furnished an update under Regulation FD by issuing a press release titled “QHSLab (OTCQB:USAQ) Issues Unaudited Financial and Operational Update Ahead of January 2026 Investor Session.” The press release is attached as Exhibit 99.1 and incorporated by reference.
The company states that the information in the press release is furnished, not filed, under the Exchange Act and is not automatically incorporated into other filings unless specifically referenced. QHSLab also emphasizes its use of its website and social media channels, including Twitter, LinkedIn, Facebook, and Instagram, as additional ways to share business and financial information that may be considered material.
QHSLab, Inc. entered into a promissory note modification and partial conversion agreement with Alex Mirakian MD PA, converting $126,548 of principal and accrued interest into 421,827 common shares at an effective price of $0.30 per share. This reduced the outstanding balance on the original 10% convertible note to $20,000 and extended its maturity date to December 31, 2026. The remaining balance is still convertible at the holder’s option at a price equal to the greater of a 25% discount to the 15‑day average market price or $0.50 per share, and the company may prepay it at any time without penalty. The shares were issued as restricted securities in a private transaction relying on Section 4(a)(2) and Rule 506 of Regulation D, with no underwriters or commissions involved.
QHSLab, Inc. disclosed that on December 26, 2025 it closed a private placement with two accredited investors for approximately $500,000 of common stock and warrants. The company issued 1,666,663 shares of common stock at $0.30 per share and 416,666 warrants to purchase common stock.
Each warrant is exercisable at $0.60 per share and expires on December 31, 2030. Net proceeds to QHSLab were in excess of $495,000, with planned use for general corporate purposes, including working capital. The securities were issued in a private offering relying on Regulation D exemptions and were sold without brokers, underwriters, or finder fees.
QHSLab also noted it issued a press release on December 29, 2025 titled “QHSLab, Inc. (OTCQB:USAQ) Completes $500K Private Placement, Enters 2026 With Clean Capital Structure,” which was furnished as an exhibit.